Pharmacology & Therapeutics

Article	Citations
Editorial Board	409
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	407
Adenosine receptor signalling as a driver of pulmonary fibrosis	340
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	270
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	263
Treatment strategies for leptomeningeal disease in patients with breast cancer	250
Inflammation, lipids, and pain in vulvar disease	225
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	206
Matrikines in the skin: Origin, effects, and therapeutic potential	190
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	183
Unfolded protein responses: Dynamic machinery in wound healing	164
SGLT2 inhibitors: Do they have antiarrhythmic properties?	162
Non-canonical G protein signaling	149
Collateral lethality: A unique type of synthetic lethality in cancers	116
Potential neonatal toxicity of new psychoactive substances	114
Treatment approaches for alcohol use disorder with metabolic dysfunction	114
The role of macrophages in asthma-related fibrosis and remodelling	110
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	109
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	108
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	107
Endothelial dysfunction as a complication of anti-cancer therapy	106
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	105
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	104
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	103
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	99

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	97
Boron in cancer therapeutics: An overview	95
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	93
TAAR1 as an emerging target for the treatment of psychiatric disorders	85
Management of drug-resistant hypertension as a heterogeneous disorder	85
Editorial Board	85
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	85
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	83
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	83
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	83
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	80
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	80
Dysregulation of metabolic pathways in pulmonary fibrosis	79
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	78
Editorial Board	78
Editorial Board	77
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	76
PGRMC1: An enigmatic heme-binding protein	74
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	72
Pharmacological treatment of cardiogenic shock – A state of the art review	71
Review: Sex-related differences in the treatment of cardiac arrhythmia	71
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	70
Natural products that alleviate depression: The putative role of autophagy	70
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	68
Bispecific antibodies for the treatment of neuroblastoma	68
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	67
DNA methylation in cell plasticity and malignant transformation in liver diseases	67
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	67
Stabilizing the neural barrier – A novel approach in pain therapy	66
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	65
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	64
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	64
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	63
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	62
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	60
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	60
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	60
Advances in pathogenesis and therapeutic strategies for osteoporosis	59
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	59
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	58
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	58
Drug-induced Torsades de pointes: Insights from a canine model of chronic atrioventricular block	58
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	58
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	58
Recent advances in riboflavin transporter RFVT and its genetic disease	56
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	56
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	56
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	54
Regulation of feeding and therapeutic application of bioactive peptides	53

Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	53
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	52
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	52
Therapeutic targeting of DNA methylation alterations in cancer	51
The role of drug-metabolizing enzymes in synthetic lethality of cancer	51
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	50
Editorial Board	49
Optimizing drug therapies in cardiac amyloidosis	49
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	48
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	48
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	48
MicroRNAs in drug addiction: Current status and future perspectives	48
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	47
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	47
Corrigendum to “Drug discovery through biophysical techniques: Methods and applications” [pharmacology and therapeutics volume 277 (2026) 108947]	47
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	47
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	47
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	47
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	46
Pharmacological potential of cyclic nucleotide signaling in immunity	46
Organic anion transporters in remote sensing and organ crosstalk	46
CDNF and ER stress: Pharmacology and therapeutic possibilities	46
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	45
Editorial Board	45
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	45
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	44
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	43
G protein-coupled estrogen receptor biased signaling in health and disease	43
The role and participation of immune cells in the endometrial tumor microenvironment	43
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	43
Oxidative stress and antioxidant therapeutic mechanisms	42
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	42
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	41
Editorial Board	41
Molecular mechanisms of ferroptosis and their involvement in brain diseases	41
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation	41
Exploring the landscape of post-translational modification in drug discovery	41
Platelet lipid metabolism in vascular thrombo-inflammation	40
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	40
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	40
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	40
RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma	40
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	40
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	40
Understanding the molecular bridges between the drugs and immune cell	40
Targeting cell cycle checkpoints for glioma therapy	39
Potential targeting of the tumor microenvironment to improve cancer virotherapy	39
Editorial Board	38
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	38
From bench to clinic: Emerging therapies for corneal scarring	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	36
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	36
Prolactin and pain of endometriosis	36
Early life adversities, psychopathologies and novel pharmacological strategies	35
Plant-derived nanovesicles and therapeutic application	35
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	35
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	35
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	35
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	35
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	35
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	35
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	35
Editorial Board	34
The antidepressant actions of ketamine and its enantiomers	34
Editorial Board	34
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	34
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	34
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	33
Anti-cancer activity of sustained release capsaicin formulations	33
Biased signaling in drug discovery and precision medicine	33
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	33
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	33
Treatment of overdose in the synthetic opioid era	33
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	32
Retina-directed gene therapy: Achievements and remaining challenges	32
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	32
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	31
Bile acids and neurological disease	31
The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy	31

Gene and stem cell therapy for inherited cardiac arrhythmias	31
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	31
The free fatty acid receptor 2 (FFA2): Mechanisms of action, biased signaling, and clinical prospects	31
Mechanistic insights into medulloblastoma relapse	31
Targeting immunoproteasome in neurodegeneration: A glance to the future	31
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	31
Resolution of inflammation in oral diseases	31
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy	31
A comprehensive review on pharmacokinetic mechanism of herb-herb/drug interactions in Chinese herbal formula	30
Editorial Board	30
Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression	30
Lessons learned from 20 years of preclinical testing in pediatric cancers	30
Spotlight on plasticity-related genes: Current insights in health and disease	30
From exploring cancer and virus targets to discovering active peptides through mRNA display	30
Human PSC-derived liver cells and their applications for disease models and drug discovery	30
Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications	30
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?	30
Artificial intelligence with mass spectrometry-based multimodal molecular profiling methods for advancing therapeutic discovery of infectious diseases	30
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities	30
Clinical advances in oncolytic virotherapy for pediatric brain tumors	30
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases	29
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance	29
Next-generation nanocarriers for therapeutic oligonucleotides: Precision targeting and stimuli-responsive cancer therapy	29
“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)	29
The future of targeted kinase inhibitors in melanoma	29
PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications	29
Formylpeptide receptors: A novel target to treat cardiometabolic complications	29
Antithrombotic therapy following transcatheter aortic valve intervention	29
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders	28
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis	28
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma	28
Potential application of natural compounds in ischaemic stroke: Focusing on the mechanisms underlying “lysosomocentric” dysfunction of the autophagy-lysosomal pathway	28
A natural products solution to diabetic nephropathy therapy	28
Editorial Board	28
Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols	28
Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies	28
Sex differences in eicosanoid formation and metabolism: A possible mediator of sex discrepancies in cardiovascular diseases	28
Antiviral drug repurposing: different approaches and the case of antifungal drugs	27
The many facets of biased signaling: Mechanisms and possible therapeutic implications	27
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure	27
Editorial Board	27
Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies	27
Advances in understanding cancer-associated neurogenesis and its implications on the neuroimmune axis in cancer	27
The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges	27
Editorial Board	27
ThermoTRP channels in pain sexual dimorphism: new insights for drug intervention	27
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies	26
The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans	26
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics	26
CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control	26
Impact of drug treatment and drug interactions in post-stroke epilepsy	26
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis	26
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer	26
Novel strategies exploiting interleukin-12 in cancer immunotherapy	26
Inflammation in kidney repair: Mechanism and therapeutic potential	25
Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions	25
The role of the STAT3 signaling transduction pathways in radioresistance	25
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response	25
The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine	25
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?	25
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease	25
Editorial Board	24
Corrigendum to “Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges” [Pharmacology & Therapeut	24
Editorial Board	24
Editorial Board	24
Functional hydrogels as therapeutic tools for spinal cord injury: New perspectives on immunopharmacological interventions	24
Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology	24
Glyoxalase I is a novel target for the prevention of metabolic derangement	23
The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?	23
Improvement of chronic metabolic inflammation and regulation of gut homeostasis: Tea as a potential therapy	23
Understanding the physiological role of NaV1.9: Challenges and opportunities for pain modulation	23
Cancer metastasis: Molecular mechanisms and clinical perspectives	23
Endothelial progenitor cells in the host defense response	23
Targeting selective autophagy in CNS disorders by small-molecule compounds	23
Corrigendum to “Game of clones: Battles in the field of carcinogenesis” [Pharmacology & Therapeutics, volume 237, Pages 108–251]	22
Overview of the role of purinergic signaling and insights into its role in cancer therapy	22
Mass spectrometry-based absolute quantitative proteomics of drug-metabolizing enzymes in human liver	22
Potassium homeostasis – Physiology and pharmacology in a clinical context	22
Pathological and pharmacological functions of the metabolites of polyunsaturated fatty acids mediated by cyclooxygenases, lipoxygenases, and cytochrome P450s in cancers	22
Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy	22
Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target	22
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors	21
Impact of G protein-coupled receptor conformation on signaling bias: Integrating simulations and biophysical experiments	21
Biased agonism in peptide-GPCRs: A structural perspective	21
Drug discovery through biophysical techniques: Methods and applications	21
Detailed curriculum vitae of HER2-targeted therapy	21
The controversial role of beta-blockers in heart failure with preserved ejection fraction	21
Neuroimmune modulators derived from natural products: Mechanisms and potential therapies	21
Biased signaling by human follicle-stimulating hormone variants	21
Small molecules as a source for acute kidney injury therapy	21
Editorial Board	20
Targeting organ-specific mitochondrial dysfunction to improve biological aging	20
Editorial Board	20
Inflammation and oxidative stress as mediators of the impacts of environmental exposures on human pregnancy: Evidence from oxylipins	20
Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension	20